Literature DB >> 17549404

Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis.

Stéphane Garcia1, Jean-Philippe Dales, Emmanuelle Charafe-Jauffret, Séverine Carpentier-Meunier, Lucile Andrac-Meyer, Jocelyne Jacquemier, Claudine Andonian, Marie-Noelle Lavaut, Claude Allasia, Pascal Bonnier, Colette Charpin.   

Abstract

c-Met is responsible for cell motility and tumour spreading. c-Met expression and signal transducers reflecting c-Met functionality were investigated in breast carcinomas, in correlation with patient outcome and tumour vasculature. Tissue microarrays of 930 breast carcinomas were constructed, categorised according to patients' follow-up (4- to 10-year follow-up; median, 6.5 years). Standardised immunocytochemical procedures were performed using anti-c-Met, -PI3K, -FAK, -JAK, and -CD146, -FYN and an automated autostainer (Ventana). High-throughput densitometry measuring the extent of immunoprecipitates was assessed by image analysis (SAMBA). c-Met overexpression correlated with poor survival along with PI3K and FAK reflecting c-Met functionality and CD146 and FYN expression in endothelial cells. Automated quantification of immunocytochemical precipitates using image analysis was shown to provide an objective means of measuring cellular proteins that are potentially relevant for current practice in pathological diagnosis and for specific therapy combining inhibitors of both c-Met and downstream transducer pathways, and of tumour angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549404

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

Review 1.  Emerging targeted agents in metastatic breast cancer.

Authors:  Dimitrios Zardavas; José Baselga; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2013-03-05       Impact factor: 66.675

2.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

3.  Gene silencing of c-Met leads to brain metastasis inhibitory effects.

Authors:  Se Jeong Lee; Ho Jun Seol; Hye Won Lee; Won Young Kang; Bong Gu Kang; Juyoun Jin; Mi-Young Jo; Younggeon Jin; Jung-Il Lee; Kyeung Min Joo; Do-Hyun Nam
Journal:  Clin Exp Metastasis       Date:  2013-04-27       Impact factor: 5.150

4.  Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.

Authors:  Xian-Zeng Hou; Wei Liu; Hai-Tao Fan; Bin Liu; Bo Pang; Tao Xin; Shang-Chen Xu; Qi Pang
Journal:  Neuro Oncol       Date:  2010-03-03       Impact factor: 12.300

5.  FYN is overexpressed in human prostate cancer.

Authors:  Edwin M Posadas; Hikmat Al-Ahmadie; Victoria L Robinson; Ramasamy Jagadeeswaran; Kristen Otto; Kristen E Kasza; Maria Tretiakov; Javed Siddiqui; Kenneth J Pienta; Walter M Stadler; Carrie Rinker-Schaeffer; Ravi Salgia
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

6.  Role of c-Met in cancer: emphasis on lung cancer.

Authors:  Ravi Salgia
Journal:  Semin Oncol       Date:  2009-04       Impact factor: 4.929

Review 7.  The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.

Authors:  Weon-Kyoo You; Donald M McDonald
Journal:  BMB Rep       Date:  2008-12-31       Impact factor: 4.778

8.  In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.

Authors:  Pablo Rosado; Paloma Lequerica-Fernández; Ignacio Peña; Laura Alonso-Durán; Juan C de Vicente
Journal:  Virchows Arch       Date:  2012-07-12       Impact factor: 4.064

9.  Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.

Authors:  C Charpin; S Giusiano; S Charfi; V Secq; S Carpentier; L Andrac; M-N Lavaut; C Allasia; P Bonnier; S Garcia
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

10.  Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival.

Authors:  Gideon Y Stein; Nir Yosef; Hadar Reichman; Judith Horev; Adi Laser-Azogui; Angelique Berens; James Resau; Eytan Ruppin; Roded Sharan; Ilan Tsarfaty
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.